

This listing of claims replaces all prior versions and listings of claims in the application.

LISTING OF CLAIMS

What is claimed is:

1. – 123. (Canceled)

124. (Currently Amended) A method of reducing complement activation ~~inflammation~~ during in gene therapy in a subject, comprising administering a composition comprising a viral vector comprising a complement modulator ~~expressed~~ displayed on the surface of the vector, wherein the complement modulator inhibits complement activation and wherein the complement modulator is encoded by the viral vector.

125. (Canceled)

126. (Withdrawn) The method of claim 124, wherein the complement inhibitor is SCR 13-15.

127. (Withdrawn) The method of claim 124, wherein the complement inhibitor is Crry.

128. – 162. (Canceled)

163. (Previously Presented) The method of claim 124, wherein the viral vector is an adenoviral vector.

164. (Previously Presented) The method of claim 124, wherein the viral vector is an AAV.

165. (Canceled)

166. (Previously Presented) The method of claim 124, wherein the complement modulator comprises two repeats of ED1 and a linker.

167. (Previously Presented) The method of claim 166, wherein the complement modulator further comprises a His-tag.

168. (Previously Presented) The method of claim 124, wherein the complement modulator comprises SEQ ID NO:9.

169. (Previously Presented) The method of claim 124, wherein the complement modulator comprises the ed1 region of the Sh-TOR protein of Schistosoma parasite.

170. (Previously Presented) The method of claim 124, wherein the viral vector further comprises a gene of interest.

171. (Previously Presented) The method of claim 124, wherein the viral vector further comprises a targeting motif.

172. (Currently Amended) The method of claim 171, wherein the targeting motif is selected from the group consisting of the tripeptide RGD sequence, ~~fiber~~-fiber-fibrin chimeras, CD40L, E-selectin targeting peptides, and SSTR-avid peptide.

173. (Previously Presented) The method of claim 124, wherein the viral vector further comprises a promoter.

174. (Previously Presented) The method of claim 124, wherein the viral vector further comprises a reporter nucleic acid.

175. (Previously Presented) The method of claim 124, wherein the viral vector further comprises a CAR binding site mutation or an ablation of integrin-binding.